Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the
rollout of effective vaccines. Therefore, it is essential to understand the levels of protection …
rollout of effective vaccines. Therefore, it is essential to understand the levels of protection …
Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
J Hu, P Peng, K Wang, L Fang, F Luo, A Jin… - Cellular & molecular …, 2021 - nature.com
Coronaviruses are enveloped, positive-stranded RNA viruses that contain the largest known
RNA genomes to date. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
RNA genomes to date. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Neutralization of SARS-CoV-2 lineage B. 1.1. 7 pseudovirus by BNT162b2 vaccine–elicited human sera
A Muik, AK Wallisch, B Sänger, KA Swanson, J Mühl… - Science, 2021 - science.org
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage
called B. 1.1. 7 (variant of concern: VOC 202012/01), which is reported to spread more …
called B. 1.1. 7 (variant of concern: VOC 202012/01), which is reported to spread more …
SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain
Tools to monitor SARS-CoV-2 transmission and immune responses are needed. We present
a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a …
a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a …
Convalescent-phase sera and vaccine-elicited antibodies largely maintain neutralizing titer against global SARS-CoV-2 variant spikes
The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic continues,
with devasting consequences for human lives and the global economy,. The discovery and …
with devasting consequences for human lives and the global economy,. The discovery and …
An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …
protection of individuals and populations against SARS-CoV-2. Moreover, passively …
[HTML][HTML] The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …